 Latest Data Page
|
Innovative academic startups 2016
|
SciCafé
|
Startups on the menu: Atreca
|
Trade Secrets Blog
|
The Bioentrepreneur blog, Trade Secrets, boasts contributors from around the globe, providing regular insight and commentary from those helping build the world's biotechnology sectors.
|
Podcast
|
The new episode of Nature Biotechnology's First Rounders podcast: Jeremy Levin is chairman and CEO of Ovid Therapeutics, formerly president and CEO of Teva Pharmaceutical Industries, and former member of the executive committee at Bristol-Myers Squibb, where he led that company's “string of pearls” strategy. His conversation with Nature Biotechnology covers shifting his mindset from treating patients to business development, his youth in South Africa, and how his past influences his view of the 2016 US presidential election results.
|
View more articles
|
| |
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department
For other enquiries, please contact our customer feedback department
Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located The Campus, 4 Crinan Street, London, N1 9XW.
© 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
|
No comments:
Post a Comment